Mabtas 100mg (Rituximab)

DESCRIPTION

Mabtas is a anticancer medicine which prevents the growth and spread of cancer cells in the body. Mabtas also indicated for the treatment of Non- Hodgkins lymphoma or chronic lymphocytic and with combination with another anticancer drugs like methotrexate is used for rheumatoid arthritis symptoms in adult treatment.

Mabtas with steroid regimen combination is given for the treatment of some rare disorders which cause blood vessels and other tissues inflammation in the body.

INDICATION

Mabtas   and hyaluronidase human injection are given alone or combination with another drugs to treat certain types of non-Hodgkin's lymphoma and chronic lymphocytic leukemia (cancer start in WBC). Mabtas   injection is also used with methotrexate (Otrexup, Rasuvo, Xatmep, others) for the treatment rheumatoid arthritis symptoms in adults that have been already treated with a some type of regimen known as tumor necrosis factor (TNF) inhibitor. Mabtas   is a type in a classification of drugs called monoclonal antibodies. Mabtas   is used to killing cancer cells to treat NHL , CLL, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis by stopping the activity of the part of the immune system that will damage the joints, veins, and other blood vessels and cause damage to organs (heart and lungs).

PHARMACOLOGY

new type of "targeted" cancer treatment and an integral part of the body's immune system. Naturally the body build antibodies in along with to an antigen which has entered the body and attach to the antigen for destruction by the immune system. An essential cells only aimed by monoclonal antibiotics, they may leads to less toxicity to healthy cell and it is usually treatment recommended only for cancers in which antigens (and the respective antibodies) have been already identified. Mabtas works by linking to the CD20 antigen on normal and malignant B-cells. Hence the body's essential immune security are initiated to attack and kill the marked B-cells. Stem cells i.eyoung cells in the bone marrow which will grow into the various cell types and do not have the CD20 antigen. After treatment,CD20 antigen allows healthy B-cells to multiply

ADME PROPERTY

ABSORPTION

Not available

DISTRIBUTION

volume of distribution is 3.1 L

METABOLISM

Mabtas   metabolized by human antimurine antibody production.

EXCRETION

not available The half life of NHL is 22 days and for RA is 18.0 days, GPA and microscopic polyangitis is 23 days.

DOSAGE MANAGEMENT

DOSAGE MANAGEMENT

Mabtas is recommended to administer only through intravenous infusion not by IV push or bolus.

BEFORE EACH INFUSION PREMEDICATE

First infusion: initially rate of 50 mg/hr is given , in not showing infusion toxicity, rate raised upto 50 mg/hr increments at intervals of 30 min and max of 400 mg/hr. Successive infusion: 100 mg/hr initiated rate , in not showing infusion toxicity, rate raised upto 100 mg/hr increments at intervals of 30 min and max of 400 mg/hr. Premedication with corticosteroids must be considered, if Mabtas combination with CHOP chemotherapy is not given.

LOW GRADE OR FOLLICULAR NON-HODGKINS LYMPHOMA

Dose is 375 mg/m2 as an IV infusion. Once weeks for 4 or 8 doses administrated for Relapsed treatment Relapsed Retreatment for once weekly for 4 doses administrated. Untreated Previously: given on day 1 of each cycle of chemotherapy, upto 8 doses. In complete or partial response of patient, start with 8 weeks for maintenance following Mabtas in combination with chemotherapy completed then administer 8weeks for 12 doses as a single agent. Once weekly for 4 dose at intervals of 6 months and max of 16 dose for Non – progression (following CVP chemotherapy completion 6 – 8 cycles) On day 1 each cycle of chemotherapy upto 8 infusions for Diffuse large B- cell NHL.

COMPONENT OF ZEVALIN FOR TREATMENT OF NHL

Prior to the administration of Indium-111-(In-111-) Zevalin and Yttrium-90- (Y-90-)Zevalin administer Mabtas infusion about 250 mg/m2 within 4 hours Before toRituxan and Y-90- Zevalin administrate Rituxan and In-111-Zevalin 7–9 days.

CHRONIC LYMPHOCYTIC LEUKEMIA

Before starting of FC chemotherapy, dose recommended is 375 mg/m2 followed 500 mg/m2 on day 1 of 2-6 cycles every 28 days.

RHEUMATOID ARTHRITIS

Mabtas is administer with methotrexate combination Mabtas administrating as two dose of 100mg IV infusion 2 weeks separated. When glucocorticoids administered as methyl prednisolone 100mg IV Subsequent course based on clinical evaluation should administer every 24 weeks, but not early than every 16 weeks.

GRANULOMATOSIS POLYANGITIS AND MICROSCOPIC POLYANGITIS

Weekly once for 4 weeks administer Dose of 375 mg/m2 IV infusion While Glucocorticoids combination with methylprednisolone by dose of 1000 mg IV/ day given for 1- 3 days and purse by oral prednisone 1 mg/kg/day are recommended for the treatment of symptoms of serious vasculitis . This drug should intiate within 14 days before or with the starting of Mabtas   and may continue during and after the 4 week course with treatment of Mabtas   drug. Safety and not established for subsequent infusion.

ADMINISTRATION

Take an Mabtas amount and diluted to final concentration of 1 mg/ml upto 4 mg/ml as infusion (containing either 0.9% Nacl or 5% dextrose in water). Invert gently the bag and mix the solution. Dispose unused drug left in vial. OVERDOSAGE: If the patients had high dose of Mabtas then seek immediately to the emergency department or poison control help line. Please consult the doctor for further clarification.

PRECAUTION

Allgeric condition against Mabtas   or any other medication informs your doctor. Concerning your past history of drug used which include in prescription, non-prescription, vitamins &supplements, nutritional products just inform the doctor. While using Mabtas   do not take any vaccination or immunization without taking advice from doctors. Avoid use of Mabtas   if you are pregnant. It will harm the baby unborn, while using Mabtas   use correct birth control to prevent pregnancy and for at least 2 weeks after your treatment ends. Mabtas   may affect the ability to have children in women. Inform your doctor if you planning to pregnant. It is unknown whether Mabtas   passes into breast milk , avoid breast-feed while on Mabtas   treatment.

SIDE EFFECTS

COMMON EFFECTS
fever and chills (flu lik symptoms)

LESS COMMON SIDE EFFECTS

Weakness; nausea; headache; cough; dyspnae; pharyngitis

DRUG INTERACTION

Mabtas   drug interaction has limited data is available at present. Combination with fludarabine or cyclophosphamide has no effects in pharmacokinetics in cll patients. Combination with methotrexate had no effects in pharmacokinetics.

CONTRAINDICATION

Hypersensitivity or murine proteins. Active severe infectons in rheumatoid arthritis Uncontrolled cardiac disease.

PREGNANCY

CategoryC : animal studies reproduction shown an adverse effect on the fetus. The drug has no sufficient and well controlled studies in humans, using in pregnant women benefits by warrant use of the drug.

LACTATION

Mabtas   excreted into human milk is unknown. Due to the drug belongs to large protein molecule, no information is available. Women should not breast feed during Mabtas   treatment and 12 months following last dose.

STORAGE

Store at 2°C – 3°C
Use the drug before expiry date
Protected from direct sunlight
Do not freeze or shake.
Keep away from the children’s
Discard the unused drug by asking the advice from doctor or pharmacist.

MISSED DOSE

If a dose missed to take at the time then have it suddenly before next dose timing, if time reach for next dose, then skip missed dose and continue and continue the regular schedule. Do not have 2 dose at a same time.